The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
Christopher Sweeney
Consultant or Advisory Role - Astellas Pharma; BIND Biosciences; Bionomics; Exelixis; Genentech; Janssen Pharmaceuticals; Roche; Sanofi
Yu-Hui Chen
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose
Glenn Liu
No relevant relationships to disclose
David Frasier Jarrard
No relevant relationships to disclose
Mario A. Eisenberger
Research Funding - Sanofi
Yu-Ning Wong
No relevant relationships to disclose
Noah M. Hahn
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Manish Kohli
No relevant relationships to disclose
Nicholas J. Vogelzang
No relevant relationships to disclose
Matthew M. Cooney
No relevant relationships to disclose
Robert Dreicer
No relevant relationships to disclose
Joel Picus
No relevant relationships to disclose
Daniel H. Shevrin
No relevant relationships to disclose
Maha Hussain
No relevant relationships to disclose
Jorge A. Garcia
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Robert S. DiPaola
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi